Supemtek®
Morbid Obesity
Assistance Publique - Hôpitaux de ParisvaccinePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 81/ 100
Competitive context
65 Active assets in the Morbid Obesity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LIDOCAINE Instituto Mexicano del Seguro Social | Phase 4 | BBB |
Colesevelam Hvidovre University Hospital | Phase 4 | BBB |
RAMIFENTANYL Hospital dos Lusíadas | Phase 4 | BBB |
Chenodeoxycholic Acid Hvidovre University Hospital | Phase 4 | BBB |
PROPOFOL G.Gennimatas General Hospital | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →